Navigation Links
Campbell Alliance Announces Windhover Top 10 Oncology Projects for 2011
Date:11/29/2011

RALEIGH, N.C., Nov. 29, 2011 /PRNewswire/ -- Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the assets chosen for the 2011 Top 10 Most Licensable Oncology Projects to Watch.  Selected projects will be discussed in more detail at the upcoming Windhover Therapeutic Area Partnerships conference (http://www.tapartnerships.com) in Boston, November 30 through December 2.

Narrowed from a field of over 1,700 oncology assets using a strict set of judging criteria, the selected projects represent what are considered the most attractive licensable oncology opportunities the industry has to offer.  Specifically, the selection team focused on what are considered "hot areas" in oncology:  those with transformational, nascent therapies where the potential for differentiation is high.  Conjugated antibody, cancer metabolism, and immuno-oncology technologies dominated the list this year.

"Our approach this year was to look at differentiated molecular pathways and technologies," said Jonathon Fendelman, Senior Practice Executive at Campbell Alliance.
"While these targeted approaches tend to address smaller patient populations initially, a great deal of potential exists for add-on indications, which makes them attractive licensing opportunities.  Further, strong differentiation raises the likelihood of reimbursement post-approval, which is key in an increasingly payer-driven market."
2011 Top 10 Most Licensable Oncology Projects to Watch
CompanyAsset/CompoundLocationWebsiteAdvaxis

ADXS-HPV

US/New Jersey

www.advaxis.comAltor

ALT-801

US/Florida

www.altorbioscience.comAveo

Ficlatuzumab

US/Massachusetts

www.aveopharma.comBiotest AG

BT-062

Germany

www.biotest.comCelldex

CDX-011

US/Massachusetts

www.celldextherapeutics.comEndocyte

EC145

US/Indiana

www.endocyte.comImmunoCellular Therapeutics

ICT-107

US/California

www.imuc.comImmune System Therapeutics 

MDX 1097

Australia

www.istl.com.auNeogenix Oncology

Ensituximab/NPC-1C

US/New York

www.neogenix.comRuga

STF-31

US/California

www.rugacorp.comCampbell Alliance has served as advisor for the oncology track of the Therapeutic Area Partnerships event since 2007.  More information on Campbell Alliance's Top 10 Oncology Projects can be found at http://www.campbellalliance.com/OncTop10.

Windhover originally announced the full list of companies selected as part of the Therapeutic Area Partnerships conference on November 1.  The list included assets from each of several therapeutic areas:  cardiovascular/metabolic, oncology, neuroscience, infectious diseases, and inflammatory/autoimmune, plus a "hot space" category, including ophthalmology, orphan diseases, and women's health.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance.  Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry.  The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales.  From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.   

 

 CONTACT:James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com
'/>"/>

SOURCE Campbell Alliance
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Appoints Dr. John Campbell Woodard as Senior Vice President of Scientific Affairs
2. Tunnell Consulting Forms Strategic Alliance With Ireland-Based Campbell Informatics
3. Campbell Alliance Announces Executive Promotions and Organizational Changes
4. Nader Naeymi-Rad Appointed CEO of Campbell Alliance
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
7. Lung Cancer Alliance Commends NCCN on Screening Guidelines
8. Lung Cancer Alliance Hails Announcement of New Erbitux(R) Data
9. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
10. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
11. Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):